ClinicalTrials.gg
Active, not recruitingNCT05453162Updated Nov 12, 2026Results posted

Circadian Influence on Prolonged Exposure Therapy for PTSD

An interventional study of Prolonged Exposure Therapy for Posttraumatic Stress Disorder in PTSD, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 12, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital — 5 open to participants now, 9 under way, none of them phase 3. Stress Disorders, Post-Traumatic · Massachusetts General Hospital.

Enrollment
20th of 27
29 · median 57
Started
2022
with 1 other
No phase
15 of 28
4 open now
Registered
18th of 28
by date

Among the 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital, this one is the 20th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2022, is one of 15 with no phase, and was the 18th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

5 of the 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital, or all of them as a file.
02

Study summary

Proposed research will examine time-of-day effects on trauma-related fear extinction using Prolonged Exposure Therapy (PE) telemedicine for Posttraumatic Stress Disorder (PTSD) in the National Center for PTSD (NCPTSD). The primary mechanistic outcome measure will be change in psychophysiological reactivity to script-driven imagery (SDI-PR) measured, in person, at pre-treatment, after 5 PE sessions (mid-treatment), and after all 10 PE sessions (post-treatment). A secondary mechanistic outcome will be session-to-session reduction in peak subjective units of distress (SUDS) ratings to imaginal exposures. The primary clinical outcome will be change in Clinican Administered PTSD Scale (CAPS-5) severity score; a secondary clinical outcome will be session-to-session reduction in self-reported PTSD symptoms using the PTSD checklist (PCL-5). Participants meeting inclusion criteria (described below) will be randomized to either PE sessions that begin from 07:00 to a time no later than 2 hours past a participant's customary rise time, or to the last treatment session of the day beginning at 16:00 or later (26 per arm). Participants will complete daily at-home imaginal-exposure homework within the same time frame as their PE sessions are scheduled, i.e., within 2 hours of awakening for morning (AM) group and between 16:00 and 2 hours before bedtime for late afternoon (PM) group.

Read the detailed description

Proposed research will examine time-of-day effects on trauma-related fear extinction using PE therapy for PTSD in the National Center for PTSD (NCPTSD). The primary mechanistic outcome measure will be change in SDI-PR; a secondary mechanistic outcome will be session-to-session reduction in peak SUDS ratings to imaginal exposures. The primary clinical outcome will be change in CAPS-5 severity score; a secondary clinical outcome will be session-to-session reduction in self-reported PTSD symptoms (PCL-5). Participants meeting inclusion criteria (described below) will be randomized to either PE sessions that begin from 07:00 to a time no later than 2 hours past a participant's customary rise time, or to the last treatment session of the day beginning at 16:00 or later. Participants will complete daily at-home imaginal-exposure homework within the same time frame as their PE sessions are scheduled (i.e., within 2 hours of awakening for morning group and between 16:00 and 2 hours before bedtime for late afternoon group). The assessment schedule will be identical for all participants. Participants who meet study inclusion criteria at screening will first begin a 7-day, pre-study sleep-monitoring period with wrist actigraphy, sleep diaries and completion of a diurnal profile of salivary cortisol levels. Trauma-related fear will be assessed using the standard SDI procedures detailed below at pre-treatment, after 5 PE sessions (mid-treatment), and after all 10 PE sessions (post-treatment). The CAPS-5 will be administered at these same times. PCL-5 measurements will be obtained at each treatment session and SUDs will be obtained during all treatment sessions that include imaginal exposure (sessions 3-8). All SDI sessions will be carried out at a standardized time of day in the late-afternoon (15:00-17:00). PE treatment will be administered at a targeted rate of once per week. At each PE and assessment session, pre-session saliva samples will be obtained for cortisol measurement and normalized using the diurnal profile of cortisol obtained during the sleep-assessment week. Participants will wear the wrist actigraph and complete sleep diaries throughout PE. The diurnal cortisol profile will be repeated at the post-treatment assessment.

03

Conditions studied

  • PTSD

Keywords

  • PTSD
  • Circadian
  • Exposure Therapy
  • Sleep
  • Cortisol
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. a diagnosis of PTSD as defined by , with a minimum CAPS severity score of 26, a minimum PCL-5 score of 31, or a score of 2 or above on CAPS-5 Item B2 (concerning distressing dreams)
  2. interest in starting a course of PE
  3. availability for appointments at that will either begin from 07:00 to a time no longer than 2 hours past their customary rise time, or to the last treatment session of the day beginning at 16:00 or later
  4. Age range of 18-70
  5. A Morningness-Eveningness Questionnaire (MEQ) score above 25.
  6. Non-exclusionary psychotropic medications must have been stable for 3 weeks prior to Screening/Assessment with intention to remain stable throughout participation.

Exclusion criteria

Exclusion Criteria:

  1. current or past history of bipolar I disorder, schizophrenic or other psychotic disorders,
  2. current organic brain disorder including moderate to severe traumatic brain injury
  3. factitious disorder or malingering
  4. pregnant or planning to become pregnant in the next four months at time of screening [if a participant does become pregnant during study procedures, the situation will be reviewed on a case-by-case basis and the participant's wishes will be considered in deciding whether the participant will continue with the study or withdraw.]
  5. current moderate or severe substance use disorder with symptoms present within the past three months
  6. diagnosed moderate to severe sleep apnea, narcolepsy, periodic limb movement, or restless legs syndrome that result in daytime sleepiness indicated by Epworth Sleepiness Scale (ESS) above 10
  7. active risk of harm to self or others
  8. evidence of hepatic or renal disease or any other acute or unstable medical condition that might interfere with safe conduct of the study
  9. current participation in trauma-focused cognitive-behavioral therapy (e.g., Cognitive Processing Therapy, Written Exposure Therapy, Eye Movement Desensitization and Reprocessing Therapy)
  10. prior treatment with an adequate dose of PE (i.e., 8 or more sessions) to the traumatic event that would be the index trauma for treatment in the study
  11. having no memory of their traumatic event
  12. daily use of benzodiazepines
  13. methadone or suboxone maintenance therapy for past opioid addiction
  14. diagnosis of Cushing's disease, Addison's disease or use of medications that target cortisol directly such as those used to treat Cushing's disease [ketoconazole, mitotane (Lysodren), metyrapone (Metopirone), and Mifepristone (Korlym, Mifeprex)], those used to treat Addison's disease [Hydrocortisone (Cortef), prednisone or methylprednisolone], as well as cortisone or dexamethasone.
  15. persons who would habitually awaken so early that more than 2 h would elapse before a morning PE session could occur; or those who engage in habitual shiftwork or transmeridian travel
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Early morning PE

    26 participants randomized to 10 weekly PE sessions in early morning (between 07:00-10:00) with homework exposures occurring occur at this same time of day.

    Behavioral: Prolonged Exposure Therapy for Posttraumatic Stress Disorder

  • Experimental
    Late afternoon PE

    26 participants randomized to 10 weekly PE sessions in late afternoon (16:00 or later) with homework exposures occurring occur at this same time of day.

    Behavioral: Prolonged Exposure Therapy for Posttraumatic Stress Disorder

Interventions

  • BehavioralProlonged Exposure Therapy for Posttraumatic Stress Disorder

    Manualized procedures deliver ten 90-minute sessions targeted to occur weekly and administered via tele-health with the same study therapist. Session 1 will focus on psychoeducation. Session 2 involves construction of the in vivo exposure hierarchy. Sessions 3-10 focus on in-session imaginal exposures to the worst trauma memory for 45-60 min followed by 15-20 min of processing the imaginal exposure. For homework, participants will be instructed to confront situations on their hierarchy on a daily basis using recording of their imaginal exposure. Subjective Units of Distress (SUDS) ratings will be taken throughout imaginal exposure exercises.

06

What researchers measure

Primary outcomes

  1. Psychophysiological Reactivity to Script-driven Imagery (SDI-PR): Primary Mechanistic Outcome

    This primary mechanistic outcome, measured before, midway and after treatment is a unitary discriminant canonical variable (SDI-PR) that measures psychophysiological reactivity while listening to 2 personalized recorded scripts that describe a participant's index trauma. For each of 3 physiological measures- heart rate (HR), skin conductance (SC),and corrugator EMG (cEMG)- a response (R) score is calculated as the difference between the average level during a 30s pre-script baseline phase and the average level during a 30s imagery phase. These 3 scores are averaged across the 2 scripts and combined using standardized weights as: SDI-PR = 0.29\*\[HRR\] +0.66\*\[SCR\] +0.38\*\[cEMGR\]. There is no absolute limit to how much physiological reactivity can increase in response to scripts, therefore, minimum and maximum scores do not exist. However, a proxy maximum and minimum SDI-PR was estimated using the largest and smallest SCR, HRR, and cEMGR in the study and are respectively, 35.041and -3.061.

    Time frame: Outcome measure 1 assessed at pre-treatment (baseline), mid-treatment (week 5), and post-treatment (week 10).

  2. Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition (CAPS-5): Primary Clinical Outcome

    This primary clinical outcome is the gold standard clinical interview for assessing PTSD severity. In CAPS-5, each of the 20 symptoms of PTSD is rated on a 5-point severity scale ranging from 0 (absent) to 4 (extreme). Total scores range from 0 to 80.

    Time frame: Outcome measure 2 assessed at pre-treatment (baseline), mid-treatment (week 5), and post-treatment (week 10).

Secondary outcomes

  1. PCL-5: PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition: Secondary Clinical Outcome

    PCL-5 contains self-ratings of how much one is bothered by each of the 20 symptoms of PTSD on a 5-point severity scale ranging from 0 (Not at all) to 4 (extremely). Outcome measure 3 is the total PTSD severity score summing all 20 items. The range of total scores for the PCL-5 is 0-80.

    Time frame: 10 weeks

  2. SUDS: Secondary Mechanistic Outcome

    A rating scale from 0 to 100 where zero represents no distress at all and 100 represents very extreme distress, fear, or anxiety. SUDS ratings are subjective and different individuals may rate the same situation differently. An individual anchors their own ratings with personal recollection of situations considered "No Distress" to "Moderate" to "Extreme Distress".

    Time frame: Starting at PE Session 3 when exposures begin

07

Results

Posted Nov 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneEarly Morning PELate Afternoon PE
Started1415
Completed97
Not completed58

Outcome measures

PrimaryPsychophysiological Reactivity to Script-driven Imagery (SDI-PR): Primary Mechanistic Outcome

This primary mechanistic outcome, measured before, midway and after treatment is a unitary discriminant canonical variable (SDI-PR) that measures psychophysiological reactivity while listening to 2 personalized recorded scripts that describe a participant's index trauma. For each of 3 physiological measures- heart rate (HR), skin conductance (SC),and corrugator EMG (cEMG)- a response (R) score is calculated as the difference between the average level during a 30s pre-script baseline phase and the average level during a 30s imagery phase. These 3 scores are averaged across the 2 scripts and combined using standardized weights as: SDI-PR = 0.29\*\[HRR\] +0.66\*\[SCR\] +0.38\*\[cEMGR\]. There is no absolute limit to how much physiological reactivity can increase in response to scripts, therefore, minimum and maximum scores do not exist. However, a proxy maximum and minimum SDI-PR was estimated using the largest and smallest SCR, HRR, and cEMGR in the study and are respectively, 35.041and -3.061.

Time frame:
Outcome measure 1 assessed at pre-treatment (baseline), mid-treatment (week 5), and post-treatment (week 10).
Reported as:
Mean · score on a scale
Psychophysiological Reactivity to Script-driven Imagery (SDI-PR): Primary Mechanistic Outcome
score on a scaleEarly Morning PELate Afternoon PE
pre treatment6.07 ± 5.902.57 ± 3.76
mid treatment2.41 ± 1.581.61 ± 2.39
post treatment1.89 ± 2.461.51 ± 2.01
PrimaryClinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition (CAPS-5): Primary Clinical Outcome

This primary clinical outcome is the gold standard clinical interview for assessing PTSD severity. In CAPS-5, each of the 20 symptoms of PTSD is rated on a 5-point severity scale ranging from 0 (absent) to 4 (extreme). Total scores range from 0 to 80.

Time frame:
Outcome measure 2 assessed at pre-treatment (baseline), mid-treatment (week 5), and post-treatment (week 10).
Reported as:
Mean · score on a scale
Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition (CAPS-5): Primary Clinical Outcome
score on a scaleEarly Morning PELate Afternoon PE
pre treatment33.71 ± 8.6935.40 ± 8.80
mid treatment27.10 ± 15.0528.25 ± 14.25
post treatment20.22 ± 13.0821.71 ± 16.88
SecondaryPCL-5: PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition: Secondary Clinical Outcome

PCL-5 contains self-ratings of how much one is bothered by each of the 20 symptoms of PTSD on a 5-point severity scale ranging from 0 (Not at all) to 4 (extremely). Outcome measure 3 is the total PTSD severity score summing all 20 items. The range of total scores for the PCL-5 is 0-80.

Time frame:
10 weeks
Reported as:
Mean · score on a scale
PCL-5: PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition: Secondary Clinical Outcome
score on a scaleEarly Morning PELate Afternoon PE
pre treatment45.98 ± 16.99246.75 ± 15.399
PE session 142.64 ± 19.97545.62 ± 13.333
PE session 237.62 ± 21.06643.54 ± 16.934
PE session 336.67 ± 19.64438.17 ± 15.959
PE session 436.13 ± 13.86136.00 ± 18.228
PE session 532.67 ± 13.94633.20 ± 16.694
PE session 631.00 ± 21.61035.00 ± 17.626
PE session 727.33 ± 17.27731.00 ± 18.735
PE session 823.78 ± 12.34727.14 ± 18.542
PE session 923.78 ± 17.33326.57 ± 19.069
PE session 1025.88 ± 17.29930.50 ± 17.524
PE session 1123.63 ± 11.95229.17 ± 16.786
post treatment18.37 ± 11.88024.83 ± 18.258
SecondarySUDS: Secondary Mechanistic Outcome

A rating scale from 0 to 100 where zero represents no distress at all and 100 represents very extreme distress, fear, or anxiety. SUDS ratings are subjective and different individuals may rate the same situation differently. An individual anchors their own ratings with personal recollection of situations considered "No Distress" to "Moderate" to "Extreme Distress".

Time frame:
Starting at PE Session 3 when exposures begin
Reported as:
Mean · score on a scale
SUDS: Secondary Mechanistic Outcome
score on a scaleEarly Morning PELate Afternoon PE
PE Session 385.00 ± 7.63885.00 ± 9.354
PE Session 481.67 ± 10.89792.38 ± 11.563
PE Session 578.13 ± 13.07687.57 ± 15.904
PE Session 666.11 ± 17.63879.71 ± 21.654
PE Session 760.00 ± 16.20277.86 ± 23.384
PE Session 862.22 ± 17.69781.57 ± 21.462
PE Session 961.25 ± 15.75583.83 ± 21.264
PE Session1050.00 ± 14.88083.00 ± 25.677

Adverse events

Collected over From time of enrollment until the post-treatment assessment, up to 30 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Early Morning PE0/14 (0%)1/14 (7.1%)2/14 (14.3%)
Late Afternoon PE0/15 (0%)0/15 (0%)1/15 (6.7%)
Most frequent serious events
Most frequent serious events
EventEarly Morning PELate Afternoon PE
hospitalizationSurgical and medical procedures1/140/15
Most frequent other events
Most frequent other events
EventEarly Morning PELate Afternoon PE
physical or emotional distressPsychiatric disorders2/141/15
ER visitSurgical and medical procedures1/141/15
Covid exposureRespiratory, thoracic and mediastinal disorders1/140/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Early Morning PELate Afternoon PETotal
Mean36.31 ± 10.2047.11 ± 13.7341.69 ± 13.06
Sex: Female, Male
Sex: Female, Male(Participants)Early Morning PELate Afternoon PETotal
Female7411
Male71118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Early Morning PELate Afternoon PETotal
Hispanic or Latino336
Not Hispanic or Latino101020
Unknown or Not Reported123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Early Morning PELate Afternoon PETotal
American Indian or Alaska Native101
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American145
White10717
More than one race145
Unknown or Not Reported000
08

Study locations

1 site
09

References and documents

Publications

  • Pace-Schott EF, Spencer RM, Vijayakumar S, Ahmed NA, Verga PW, Orr SP, Pitman RK, Milad MR. Extinction of conditioned fear is better learned and recalled in the morning than in the evening. J Psychiatr Res. 2013 Nov;47(11):1776-84. doi: 10.1016/j.jpsychires.2013.07.027. Epub 2013 Aug 28. PubMed 23992769 ↗
  • Pace-Schott EF, Germain A, Milad MR. Effects of sleep on memory for conditioned fear and fear extinction. Psychol Bull. 2015 Jul;141(4):835-57. doi: 10.1037/bul0000014. Epub 2015 Apr 20. PubMed 25894546 ↗
  • Meuret AE, Rosenfield D, Bhaskara L, Auchus R, Liberzon I, Ritz T, Abelson JL. Timing matters: Endogenous cortisol mediates benefits from early-day psychotherapy. Psychoneuroendocrinology. 2016 Dec;74:197-202. doi: 10.1016/j.psyneuen.2016.09.008. Epub 2016 Sep 15. PubMed 27664810 ↗
  • Pace-Schott EF, Germain A, Milad MR. Sleep and REM sleep disturbance in the pathophysiology of PTSD: the role of extinction memory. Biol Mood Anxiety Disord. 2015 May 29;5:3. doi: 10.1186/s13587-015-0018-9. eCollection 2015. PubMed 26034578 ↗
  • Meuret AE, Trueba AF, Abelson JL, Liberzon I, Auchus R, Bhaskara L, Ritz T, Rosenfield D. High cortisol awakening response and cortisol levels moderate exposure-based psychotherapy success. Psychoneuroendocrinology. 2015 Jan;51:331-40. doi: 10.1016/j.psyneuen.2014.10.008. Epub 2014 Oct 16. PubMed 25462905 ↗
  • Brueckner AH, Lass-Hennemann J, Wilhelm FH, Ferreira de Sa DS, Michael T. Cortisol administration after extinction in a fear-conditioning paradigm with traumatic film clips prevents return of fear. Transl Psychiatry. 2019 Apr 8;9(1):128. doi: 10.1038/s41398-019-0455-0. PubMed 30962423 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We will share data every January 15 and July 15 with the NIMH Data Archives (NDA) under a NIMH Data Repositories Data Submission Agreement between NIMH and VA Boston Health System (VABHS). Data sharing is required for all NIMH-funded research projects. The NDA DSA will be approved by the VABHS IRB. Each participant will be assigned Global Unique ID (GUID) and data shared will contain no identifiable information. Shared data will include scored psychophysiological, self-report instruments, cortisol, actigraphy, and fully de-identified demographic data.

Supporting information: Study protocol

Time frame: Study data will become available following the end of the study and the publication of results.

Access criteria: Investigators can apply to the NIMH Data Archive (NDA) for permission to use these data.

Data sharing details ↗ · nda.nih.gov

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Aug 2025, 37 months.

Results were first posted in Nov 2026, 1 year 3 months after primary completion.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 37 months is close to that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Sep 2027, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2022
First posted
Jul 12, 2022
StartActual
Jul 1, 2022
Primary completionActual
Aug 1, 2025
CompletionEst.
Sep 1, 2027was Sep 2026
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Study completion
Sep 1, 2026→Sep 1, 2027
Nov 12, 2026
Enrollment
52 (estimated)→29 (actual)
Nov 12, 2026
Primary outcomes
2 edited, 4 removed
What changed in the outcomes
  • EditedPsychophysiological reactivityReactivity to scriptScript-driven imageryImagery (SDI-PR): Primary Mechanistic OutcomeTime frame: Between days -7 to -1, Baseline → Outcome measure 1 assessed at pre-treatment (baseline), mid-treatment (week 5), and post-treatment (week 10).
  • EditedClinician-Administered PTSD scaleScale for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition (CAPS-5): Primary Clinical OutcomeTime frame: Between days -7 to -1, Baseline → Outcome measure 2 assessed at pre-treatment (baseline), mid-treatment (week 5), and post-treatment (week 10).
  • RemovedPsychophysiological reactivity to script-driven imagery (SDI-PR): Primary Mechanistic OutcomeTime frame: Between days 29-34, mid-treatment
  • RemovedPsychophysiological reactivity to script-driven imagery (SDI-PR: )Primary Mechanistic OutcomeTime frame: Between days 64-71, post-treatment
  • RemovedCAPS-5: Primary Clinical OutcomeTime frame: Between days 29-34, mid-treatment
  • RemovedCAPS-5: Primary Clinical OutcomeTime frame: Between days 64-71, post-treatment
Nov 12, 2026
Secondary outcomes
2 time frame changed, 27 removed, 1 description edited, 2 more
What changed in the outcomes
  • RemovedSubjective Units of Distress (SUDS): Secondary Mechanistic OutcomeTime frame: Day 14 Peak SUDS during PE therapy session 3
  • RemovedSUDS: Secondary Mechanistic OutcomeTime frame: Day 28 Peak SUDS during PE therapy session 5
  • RemovedSUDS: Secondary Mechanistic OutcomeTime frame: Day 35 Peak SUDS during PE therapy session 6
  • RemovedSUDS: Secondary Mechanistic OutcomeTime frame: Day 42 Peak SUDS during PE therapy session 7
  • RemovedSUDS: Secondary Mechanistic OutcomeTime frame: Day 49 Peak SUDS during PE therapy session 8
  • RemovedSUDS: Secondary Mechanistic OutcomeTime frame: Day 56 Peak SUDS during PE therapy session 9
  • RemovedSUDS: Secondary Mechanistic OutcomeTime frame: Day 63 Peak SUDS during PE therapy session 10
  • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 7 PCL-5 score at PE therapy session 2
  • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 14 PCL-5 score at PE therapy session 3
  • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 21 PCL-5 score at PE therapy session 4
  • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 28 PCL-5 score at PE therapy session 5
  • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 35 PCL-5 score at PE therapy session 6
  • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 42 PCL-5 score at PE therapy session 7
  • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 49 PCL-5 score at PE therapy session 8
  • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 56 PCL-5 score at PE therapy session 9
  • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 63 PCL-5 score at PE therapy session 10
  • Time frameSUDS: Secondary Mechanistic OutcomeDay 21 Peak SUDS during PE therapy session 4 → Starting at PE Session 3 when exposures begin
  • Time framePCL-5: PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition: Secondary Clinical OutcomeDay 0 PCL-5 score at PE therapy session 1 → 10 weeks
  • DescriptionPCL-5: PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition: Secondary Clinical Outcome: how it is measured was reworded
  • Removedother outcomeSalivary cortisolTime frame: Between days -7 to -1, baseline
  • Removedother outcomeSalivary cortisolTime frame: Day 0, therapy session 1
  • Removedother outcomeSalivary cortisolTime frame: Day 7, therapy session 2
  • Removedother outcomeSalivary cortisolTime frame: Day 14, therapy session 3
  • Removedother outcomeSalivary cortisolTime frame: Day 21, therapy session 4
  • Removedother outcomeSalivary cortisolTime frame: Day 28, therapy session 5
  • Removedother outcomeSalivary cortisolTime frame: Between days 29-34, mid-treatment assessment
  • Removedother outcomeSalivary cortisolTime frame: Day 35, therapy session 6
  • Removedother outcomeSalivary cortisolTime frame: Day 42, therapy session 7
  • Removedother outcomeSalivary cortisolTime frame: Day 49, therapy session 8
  • Removedother outcomeSalivary cortisolTime frame: Day 56, therapy session 9
  • …and 2 more, on the record history on ClinicalTrials.gov ↗
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Study completion Sep 1, 2026→Sep 1, 2027
    Enrollment 52 (estimated)→29 (actual)
    Primary outcomes 2 edited, 4 removed
    What changed in the outcomes
    • EditedPsychophysiological reactivityReactivity to scriptScript-driven imageryImagery (SDI-PR): Primary Mechanistic OutcomeTime frame: Between days -7 to -1, Baseline → Outcome measure 1 assessed at pre-treatment (baseline), mid-treatment (week 5), and post-treatment (week 10).
    • EditedClinician-Administered PTSD scaleScale for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition (CAPS-5): Primary Clinical OutcomeTime frame: Between days -7 to -1, Baseline → Outcome measure 2 assessed at pre-treatment (baseline), mid-treatment (week 5), and post-treatment (week 10).
    • RemovedPsychophysiological reactivity to script-driven imagery (SDI-PR): Primary Mechanistic OutcomeTime frame: Between days 29-34, mid-treatment
    • RemovedPsychophysiological reactivity to script-driven imagery (SDI-PR: )Primary Mechanistic OutcomeTime frame: Between days 64-71, post-treatment
    • RemovedCAPS-5: Primary Clinical OutcomeTime frame: Between days 29-34, mid-treatment
    • RemovedCAPS-5: Primary Clinical OutcomeTime frame: Between days 64-71, post-treatment
    Secondary outcomes 2 time frame changed, 27 removed, 1 description edited, 2 more
    What changed in the outcomes
    • RemovedSubjective Units of Distress (SUDS): Secondary Mechanistic OutcomeTime frame: Day 14 Peak SUDS during PE therapy session 3
    • RemovedSUDS: Secondary Mechanistic OutcomeTime frame: Day 28 Peak SUDS during PE therapy session 5
    • RemovedSUDS: Secondary Mechanistic OutcomeTime frame: Day 35 Peak SUDS during PE therapy session 6
    • RemovedSUDS: Secondary Mechanistic OutcomeTime frame: Day 42 Peak SUDS during PE therapy session 7
    • RemovedSUDS: Secondary Mechanistic OutcomeTime frame: Day 49 Peak SUDS during PE therapy session 8
    • RemovedSUDS: Secondary Mechanistic OutcomeTime frame: Day 56 Peak SUDS during PE therapy session 9
    • RemovedSUDS: Secondary Mechanistic OutcomeTime frame: Day 63 Peak SUDS during PE therapy session 10
    • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 7 PCL-5 score at PE therapy session 2
    • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 14 PCL-5 score at PE therapy session 3
    • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 21 PCL-5 score at PE therapy session 4
    • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 28 PCL-5 score at PE therapy session 5
    • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 35 PCL-5 score at PE therapy session 6
    • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 42 PCL-5 score at PE therapy session 7
    • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 49 PCL-5 score at PE therapy session 8
    • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 56 PCL-5 score at PE therapy session 9
    • RemovedPCL-5: Secondary Clinical OutcomeTime frame: Day 63 PCL-5 score at PE therapy session 10
    • Time frameSUDS: Secondary Mechanistic OutcomeDay 21 Peak SUDS during PE therapy session 4 → Starting at PE Session 3 when exposures begin
    • Time framePCL-5: PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition: Secondary Clinical OutcomeDay 0 PCL-5 score at PE therapy session 1 → 10 weeks
    • DescriptionPCL-5: PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition: Secondary Clinical Outcome: how it is measured was reworded
    • Removedother outcomeSalivary cortisolTime frame: Between days -7 to -1, baseline
    • Removedother outcomeSalivary cortisolTime frame: Day 0, therapy session 1
    • Removedother outcomeSalivary cortisolTime frame: Day 7, therapy session 2
    • Removedother outcomeSalivary cortisolTime frame: Day 14, therapy session 3
    • Removedother outcomeSalivary cortisolTime frame: Day 21, therapy session 4
    • Removedother outcomeSalivary cortisolTime frame: Day 28, therapy session 5
    • Removedother outcomeSalivary cortisolTime frame: Between days 29-34, mid-treatment assessment
    • Removedother outcomeSalivary cortisolTime frame: Day 35, therapy session 6
    • Removedother outcomeSalivary cortisolTime frame: Day 42, therapy session 7
    • Removedother outcomeSalivary cortisolTime frame: Day 49, therapy session 8
    • Removedother outcomeSalivary cortisolTime frame: Day 56, therapy session 9
    • …and 2 more, on the record history on ClinicalTrials.gov ↗
    + 3 other changes: verification date, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05453162
Collaborators
VA Boston Healthcare System, National Institute of Mental Health (NIMH)
Responsible party
Edward F. Pace-Schott (Assistant Professor of Psychiatry, Massachusetts General Hospital) — Principal investigator
First posted
Jul 12, 2022
Start date
Jul 1, 2022
Primary completion
Aug 1, 2025
Completion
Sep 1, 2027 (estimated)
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Edward F Pace-Schott, PhD
principal investigator · Massachusetts General Hospital
Suzanne L Pineles, PhD
principal investigator · VA Boston Health System, Boston University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion